8-K: Aptevo Therapeutics Announces 100% Remission Rate in Frontline AML Trial

Aptevo Therapeutics reports that all patients in the first cohort of their RAINIER trial achieved remission within 30 days, including two with complete elimination of cancer cells.

Summary

• Aptevo Therapeutics announced that 100% of patients in Cohort 1 of their RAINIER trial for frontline acute myeloid leukemia (AML) achieved remission within 30 days.
• Two out of the three patients in Cohort 1 achieved complete remission with minimal residual disease (MRD)-negative status, indicating a 100% elimination of cancer cells.
• These results build upon previous data where 100% of frontline patients also achieved remission.
• Across both trials, 86% of patients went into remission within 30 days of their first treatment.
• The drug, mipletamig, is being investigated in combination with venetoclax and azacitidine, a standard of care for AML.
• Mipletamig has shown a favorable safety and tolerability profile in the trials.
• Cohort 2 enrollment is now commencing for the RAINIER trial.
• The RAINIER trial is a Phase 1b/2 dose optimization study with up to 39 patients across five dose levels.
• The trial is being conducted in two parts: a Phase 1b dose optimization study followed by a Phase 2 study.

Sentiment

Score: 9

Explanation: The document presents very positive clinical trial results with a 100% remission rate and MRD-negative status in some patients, indicating a high potential for the drug. The management commentary is also very positive. The only negative is the small sample size.

Positives

• The 100% remission rate in Cohort 1 is a significant positive outcome.
• The achievement of MRD-negative status in two patients is a strong indicator of treatment effectiveness.
• The rapid remission rate of 86% across both trials is very encouraging.
• The favorable safety and tolerability profile of mipletamig is a positive attribute.
• The trial is progressing to Cohort 2 enrollment, indicating continued development.
• Mipletamig's orphan drug designation provides potential market exclusivity.

Risks

• The results are based on a small sample size of three patients in Cohort 1.
• The trial design includes combination therapies, which may make it difficult to isolate the benefits of mipletamig.
• There are risks associated with clinical development, including unexpected safety issues.
• The company faces competition from other products in the market.
• There are risks related to the company's ability to raise funds or enter into strategic partnerships.
• The company is subject to macroeconomic and geopolitical risks.

Future Outlook

The company anticipates sharing new results as they become available and is commencing enrollment for Cohort 2 of the RAINIER trial. They are also continuing to evaluate ALG.APV-527 in a Phase 1 clinical trial for solid tumors.

Management Comments

• Marvin White, President and CEO of Aptevo, stated that the Cohort 1 results add to an already compelling story that highlights mipletamig's potential to elevate the frontline AML treatment paradigm.
• Marvin White also noted the 100% remission rate in Cohort 1 and the 100% remission rate in frontline patients in the completed dose expansion trial.
• Dirk Huebner, MD, Chief Medical Officer at Aptevo, stated that achieving remission in all three Cohort 1 patients is highly encouraging, particularly when viewed alongside prior trial results.
• Dirk Huebner also highlighted that one of the MRD-negative patients had a TP53 mutation, a subgroup known for its poor prognosis.

Industry Context

This announcement is significant in the context of the AML treatment landscape, where new therapies are needed to improve patient outcomes. The high remission rates and MRD-negative status achieved with mipletamig could position it as a potential transformative treatment option.

Comparison to Industry Standards

• The 100% remission rate in Cohort 1 is a very strong result compared to typical outcomes in frontline AML treatment.
• Standard treatments for AML often involve chemotherapy, which can have significant side effects and may not achieve complete remission in all patients.
• The achievement of MRD-negative status in two patients is a particularly positive outcome, as it is associated with longer-lasting remissions and improved survival rates.
• Companies such as AbbVie and Genentech have established treatments for AML, but Aptevo's approach with a bispecific antibody offers a different mechanism of action.
• The use of a CD3 derived from CRIS-7 to reduce the likelihood and severity of CRS is a differentiating factor compared to other bispecific antibodies.

Stakeholder Impact

• Shareholders will likely view the positive clinical trial results favorably.
• Patients with AML may benefit from this potential new treatment option.
• Employees of Aptevo may be motivated by the positive progress of the clinical trial.
• The company's partners and collaborators may see increased value in their relationships with Aptevo.

Next Steps

• Enrollment for Cohort 2 of the RAINIER trial is commencing.
• The company will continue to share new results as they become available.
• Further study of mipletamig in a Phase 1b dose optimization trial will continue.
• The company will continue to evaluate ALG.APV-527 in a Phase 1 clinical trial for solid tumors.

Key Dates

Keywords

AML, acute myeloid leukemia, mipletamig, bispecific antibody, immunotherapy, cancer, remission, MRD-negative, RAINIER trial, clinical trial, ADAPTIR, ADAPTIR-FLEX